A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Apolipoprotein C-III (apoC-III) inhibits triglyceride hydrolysis and has been implicated in coronary artery disease. Through a genome-wide association study, we have found that about 5% of the Lancaster Amish are heterozygous carriers of a null mutation (R19X) in the gene encoding apoC-III ( APOC3 ) and, as a result, express half the amount of apoC-III present in noncarriers. Mutation carriers compared with noncarriers had lower fasting and postprandial serum triglycerides, higher levels of HDL-cholesterol and lower levels of LDL-cholesterol. Subclinical atherosclerosis, as measured by coronary artery calcification, was less common in carriers than noncarriers, which suggests that lifelong deficiency of apoC-III has a cardioprotective effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function variants of APOC3 that result in reduced synthesis of the protein are associated with absent or low circulating apoCIII levels, increased efficiency of TG removal from TRL, and lower plasma TG levels,59,60”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, rare heterozygous LOF variants in APOC3 encoding apo C-III are associated with ∼50% reduced TG levels and significantly increased clearance of very-low-density lipoprotein (VLDL).8,9”
From Clinical review on triglycerides (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Founder populations (such as those from Finland and Iceland) have provided multiple examples of otherwise rare risk alleles driven to higher frequency locally through drift and/or selection49–52.”
From A brief history of human disease genetics (2020) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups
Detrano, R., Guerci, A. D., Carr, J. J., Bild, D. E., Burke, G., Folsom, A. R., Liu, K., Shea, S., Szklo, M., Bluemke, D. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa072100 · Cited by 2,989
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107332 · Cited by 1,443
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Cited by
Items 601–682 of 682
Translating Lipoprotein Genetics Into New Therapies
Hegele, R. A. (2026) · Circulation Research · doi:10.1161/circresaha.126.328828 · Cited by 2
Ma, Q., Wu, H., Liu, Y.-M., Zhao, P., Li, X., & Wen, J. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i20.4256 · Cited by 1
Hypertriglyceridemia (> 150 mg/dL) as a marker of cardiovascular risk
López-Miranda, J. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.500822 · Cited by 2
Maternal inheritance of severe hypertriglyceridemia impairs glucose metabolism in offspring
Ma, Y., Caiguo, Y., Kayoumu, A., Xin, G., Zhili, J., & George, L. (2015) · Journal of Biomedical Research · doi:10.7555/jbr.29.20140139 · Cited by 1
“As an inhibitor of LPL [9] , high plasma levels of ApoCIII are closely related to severity of human HTG [10] , while low plasma levels of ApoCIII are associated with low plasma TG and even with decreased incidence of coronary artery disease (CAD) as defined by angiography [11] .”
BackgroundHe, L., Sillanpää, M. J., Ripatti, S., & Pitkäniemi, J. M. (2014) · Genetic Epidemiology · doi:10.1002/gepi.21804 · Cited by 1
Hypertriglyceridemia, remnant cholesterol and cardiovascular risk: what genes can say
Kei, A. A., & Elisaf, M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12762 · Cited by 1
Jung, D., & Jin, H. (2016) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2016.22.3.107 · Cited by 1
“Moreover, there are many reports that PARK2 gene associated with various metabolic traits including insulin-related traits (Ober et al., 2009; Pollin et al., 2008; Hiura et al., 2010; Paternoster et al., 2011; Jin et al., 2014).”
BackgroundThe GGLEAM Study: Understanding Glaucoma in the Ohio Amish
Waksmunski, A. R., Song, Y. E., Kinzy, T. G., Laux, R. A., Sewell, J. L., Fuzzell, D., Fuzzell, S. L., Miller, S. D., Wiggs, J. L., Pasquale, L. R., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18041551 · Cited by 2
Genetics of healthy aging and longevity
Pavlova, E. V., Ерина, А. М., Rotar, O. P., Kostareva, A. A., Artomov, M., & Конради, А. О. (2024) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2024-2407 · Cited by 1
Contribución de la apolipoproteína CIII a la aterogenicidad de las dislipidemias
Camejo, G., & Davidsson, P. (2012) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2012.02.006 · Cited by 2
A Closer Look at Cardioprotective Function of HDL: Revise the HDL – Cholesterol Hypothesis?
Meiliana, A., & Wijaya, A. (2014) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v6i1.40 · Cited by 1
Therapies Targeting HDLc Levels and HDL Function
Vitali, C., & Cuchel, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812513-7.00012-4 · Cited by 2
Genetik der Leistungsfähigkeit und Trainierbarkeit
Blume, K., Pitsiladis, Y. P., Wang, G., & Wolfarth, B. (2017) · Springer eBooks · doi:10.1007/978-3-7091-1591-6_17 · Cited by 4
Kathiresan, S., & Rader, D. J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374934-5.00023-4 · Cited by 3
Low cholesterol syndrome and drug development
Handhle, A., Viljoen, A., Ramachandran, R., & Wierzbicki, A. S. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000745 · Cited by 3
“In contrast, apoC-3 R19X null mutation reduces apoC-3 by 40% leading to lower postprandial triglycerides, higher HDL-C and a lower coronary artery calcification (CAC) score [42].”
BackgroundMeisenberg, G., & Simmons, W. H. (2012) · Elsevier eBooks · doi:10.1016/b978-0-323-07155-0.00025-3 · Cited by 1
Genetics and Valve Calcification ∗
Brown, W. V. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.048 · Cited by 1
“Recently, the availability of familial and genetic linkage of apoCIII deficiency has been associated with reduced triglycerides and an associated reduction in coronary calcium scores in the Amish and in other populations (18,19).”
BackgroundVitali, C., Stankov, S. G., Khetarpal, S. A., Millar, J. S., Mayne, L. C., Englander, S. W., Hand, N. J., Lund‐Katz, S., Phillips, M. C., & Rader, D. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.02.183178 · Cited by 1
Stankov, S. G., Vitali, C., Park, J., Nguyen, D., Mayne, L. C., Englander, S. W., Levin, M. G., Vujković, M., Hand, N. J., Phillips, M. C., et al. (2023) · medRxiv · doi:10.1101/2023.02.21.23286268 · Cited by 1
Bench to all Bedsides in Genomics and Precision Medicine
Tcheandjieu, C., Robinson, C., & Natarajan, P. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039202 · Cited by 1
Clinical, cellular, and genomic consequences of a population-enriched SETD1A missense variantPreprint
Ament, S. A., Lease, R., Oshone, R., Ahmed, Y., Ali, S., Arjona, S. P., Choe, J., Colantuoni, C., Cortes-Gutierrez, M., Herb, B. R., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9900286/v1 · Cited by 1
“Studies of population-99 enriched variants have proven invaluable in characterizing disease mechanisms and therapeutic opportunities in a variety of common illnesses 23 – 26 .”
Self-citationKuipers, A. L. (2011) · D-Scholarship@Pitt (University of Pittsburgh)
Role of the Endothelium in Lipoprotein Metabolism
von Eckardstein, A., & Rohrer, L. (2009) · Springer eBooks · doi:10.1007/978-3-642-00300-4_7
Herbst, L. (2012) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-11667
Studies of Atherogenic Lipoproteins Using Mass Spectrometry-Based Lipidomics
Ståhlman, M. (2010) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Genomics of Myocardial Infarction
Hubbard, C. A., & Topol, E. J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374934-5.00024-6
Apolipoprotein CIII and Ljungan virus in diabetes
Holmberg, R. (2010) · Figshare
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Little, P. J., Chait, A., Januszewski, A. S., Bobik, A., O'Neal, D. N., & Jenkins, A. J. (2013) · Contemporary diabetes · doi:10.1007/978-1-4614-7554-5_23
Johansen, C. T., MacDonald, A., & Hegele, R. A. (2013) · Wiley eBooks · doi:10.1002/9780470015902.a0025307
Singh, J. (2014) · D-Scholarship@Pitt (University of Pittsburgh)
Galton, D. J., Rees, A., & Ferns, G. (2010) · QJM · doi:10.1093/qjmed/hcq235
Harahsheh, A. S., Clauss, S. B., & Mietus‐Snyder, M. (2014) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-014-0381-x · Cited by 1
Hypertriglyceridemia: the future of genetics to guide individualized therapeutic strategies
Moens, S. J. B., Hassing, C., Nieuwdorp, M., Stroes, E. S. G., & Dallinga‐Thie, G. M. (2013) · Clinical Lipidology · doi:10.2217/clp.13.23
Cardiovascular Risk in the Old Order Amish
Peltsverger, M. Y., & Celi, F. S. (2011) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-011-0163-7
“Pollin et al. [ 40 ] (2008) 809 Demonstrated that 5% of the OOA are heterozygous carriers of a null mutation (R19X) in the gene encoding apoC-III; therefore they have apoC-III deficiency, which is associated with higher level of HDL-C and lower level of LDL-C as well as lower CAC quantity”
BackgroundExamination of Genetic Components Affecting Human Obesity-Related Quantitative Traits
Kettunen, J. (2010) · STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) · Cited by 1
Novel factors affecting clearance of triacylglycerol-rich lipoproteins from blood
Nilsson, S. K. (2010)
Research progress in heritable dyslipidemia
He, Y., Xu, M., Yu, H., Geng, J., Shi, S., Xue, L., Lu, Z., & Guan, M. (2013) · Hereditas (Beijing) · doi:10.3724/sp.j.1005.2013.01237
“[DOI] [19] Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR.”
BackgroundMikrodeletionen 15q13.3, 16p13.11 und 15q11.2 in Epilepsien des Kindes- und Jugendalters
Obermeier, T. (2015) · MACAU: Open Access Repository of Kiel University (University Library Kiel)
Apolipoprotein C-III's role in cardiovascular diseases, a short review
Emilian, O. G. (2014) · ScienceOpen Research · doi:10.14293/s2199-1006.1.sor-med.afafp0.v1
Mendel, Molecular Biology, and Apolipoprotein C-III: A Heady Combination
Patel, S. B. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.1506
Amati, F., & Widmann, C. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000118
Genome-Scale Genetics: Lessons from Founder Populations
Kenny, E. E. (2010) · Digital Commons - RU (Rockefeller University) · doi:10.48496/9v1q-rb59
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American
Lennie, T. A., Levi, M., Mazzone, T., Pennathur, S., Goldberg, A. C., Howard, W. J., Jacobson, M. Z., Stone, N. J., Ballantyne, C. M., Bittner, V., et al. (2013)
West, G. (2017) · OpenCommons - UConn (University of Connecticut)
Clinical Lipidology Roundtable Discussion Clinical use of genetic typing in human lipid disorders
Brown, W. V., Breslow, J. L., Ballantyne, C. M., & Candler, C. H. (2012)
VIII. Development of New Strategy and Modality of Lipid Management
Okazaki, H. (2017) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.106.735
Genetic and Epigenetic Regulations of Post-prandial Lipemia
Xu, H. (2018) · Current Genetic Medicine Reports · doi:10.1007/s40142-018-0146-9
Santoso, A. (2015) · Indonesian Journal of Cardiology · doi:10.30701/ijc.v35i3.423
Åvall, K., Berggren, P., & Juntti‐Berggren, L. (2018) · Laboratory Animal Research · doi:10.5625/lar.2018.34.3.126
Triglycerides: Mendelian Randomization Studies Suggest Causal Role, but How to Treat in 2019?
Park, J. E., & Miller, M. J. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0603-3
Self-citationRegulation of Lipoprotein Lipase Activity : an In-vitro Study of a Complex and Dynamic System
Kovrov, O. (2019) · DiVA at Umeå University (Umeå University)
Dissecting the role of apolipoprotein CIII in diabetic wound healing
Cho, M. M. W. (2019) · doi:10.32657/10220/48515 · Cited by 1
Kathiresan, S., & Rader, D. J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382227-7.00045-8
Finding the Missing Heritability: Gene Mapping Strategies for Complex Pedigrees.
Shah, K. P. (2013) · Deep Blue (University of Michigan)
The Genomic Landscape of the Old Order Amish.
Hout, V., & Cristopher, V. (2011) · Deep Blue (University of Michigan)
Kontush, A., & Chapman, M. J. (2011) · Wiley eBooks · doi:10.1002/9781118158678.ch6
Musunuru, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823484-6.00009-8
(2009) · Nature Medicine · doi:10.1038/nm0109-6
Hussain, A., & Ballantyne, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00028-5
Impact of Rare and Common Genetic Variants on Lipoprotein Metabolism
Motazacker, M. M., Kastelein, J. J. P., & Kuivenhoven, J. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00006-2
Weekly Journal Scan: a novel RNA-based approach to the treatment of hypertriglyceridaemia
Galiuto, L., & Volpe, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae351 · Cited by 1
Metabolomics Ex/GWAS in the Amish reveals novel insights into cardiometabolic disease pathwaysPreprint
Jallow, M. W., Tzoneva, G., Ye, B., Backman, J., Zavala, V. A., Sosina, O. A., Kapoor, M., Verweij, N., Landheer, K., Geraghty, B. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.04.667775 · Cited by 2
Self-citationExonic Variation and Its Clinical Impact in 7221 Old Order Amish
Mitchell, B. D., Onyenobi, E., Lewis, J. P., Gaynor, B. J., Perry, J. A., Maloney, K. A., O’Connell, J. R., Tiner, J. C., Beitelshees, A. L., Hout, C. V. V., et al. (2025) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.64212
“…have also uncovered genetic variants that influence more common disorders and traits such as cardiovascular disease, lipid disorders, diabetes, and pharmacogenetics (Albert et al. 2014; Horenstein et al. 2013; Montasser et al. 2021; Pollin et al. 2008; Shen et al. 2010; Shuldiner et al. 2009).”
InfluentialSelf-citationApolipoproteins and cardiovascular diseases
Kaur, A., Saha, S., Ujjainiya, R., Ray, A., Basak, T., & Sengupta, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19116-9.00032-4
Phase Separation Contributes to Pathogenicity for Nonsense Mediated Decay-Escaping Variant AllelesPreprint
Xu, J., Schmidt, J., Campbell, A., Bozkurt‐Yozgatli, T., Egab, I., Mestroni, L., Taylor, M., Posey, J. E., Gibbs, R. A., Boerwinkle, E., et al. (2025) · medRxiv · doi:10.64898/2025.12.01.25341387
Goyal, S., Tanigawa, Y., Zhang, W., Chai, J.-F., Almeida, M., Sim, X., Lerner, M., Chainakul, J., Ramiu, J. G., Seraphin, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16655697
Lynch, M. T., Maloney, K. A., Xu, H., Perry, J. A., Center, R. G., Shuldiner, A. R., & Mitchell, B. D. (2023) · Figshare · doi:10.6084/m9.figshare.22618709
Self-citationLynch, M. T., Maloney, K. A., Xu, H., Perry, J. A., Center, R. G., Shuldiner, A. R., & Mitchell, B. D. (2023) · Figshare · doi:10.6084/m9.figshare.22618718
Self-citationVega, J. A., Torres, B., Alberto Maiz, G., & Santos, J. L. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1749264
Apolipoprotéine C3 : élément essentiel du métabolisme lipidique et nouvelle cible thérapeutique
Akkoura, L., & Vergès, B. L. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.009
Burhan, M., Ibrahim, T., Naveed, M. A., Ansari, Z., Ansab, M., Fatima, K., Ashraf, S., Shahid, Z. U. A., Raza, A., & Raza, S. H. A. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.03.052
Clinical Assessment of Anti-Atherogenic Function of HighDensity Lipoprotein (HDL)
Ma, F. (2018) · theses.fr (ABES) · doi:10.70675/aec01babza8edz47a2zb4d4zc7c3be00b185
田, 薇. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641488
Revisiting Founder Populations in an Age of Global Biobanks
Caggiano, C., Shemirani, R., & Kenny, E. E. (2026) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-020525-034901 · Cited by 1
The Use of Population Isolates to Identify Metabolic Syndrome's Genetic Aetiology
Meyjes-Brown, J., Sutherland, H. G. E., Lea, R. A., & Griffiths, L. R. (2026) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.70262
“This variant and association had been reported previously, but had been thought to be private to an Amish study population.”
InfluentialWu, C., Sang, J., Xu, Q., Zhan, Y., Yuan, S.-J., Ge, Y.-Y., Yu, X.-J., Zheng, X., Wang, X.-F., He, X.-M., et al. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01987-w
“Additionally, the identification of naturally protective alleles has increasingly facilitated the translation from genetic associations to therapeutic drug development (Stitz-iel et al. 2017, Pollin et al. 2008).”
Treatment of severe hypertriglyceridemia: a new era dawns
Larouche, M., & Gaudet, D. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag280
Tsimikas, S., Morgan, E. S., Sharma, J., Lin, T., Mullick, A. E., Prakash, T. P., Swayze, E. E., & Prohaska, T. A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.08.012
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
Aslesh, T., & Yokota, T. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5476-7_5
Olezarsen for the Treatment of Hypertriglyceridemia
Rodriguez, A. S. H., & Yokota, T. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5476-7_6
Apolipoprotein CIII as a therapeutic target in obesity-associated metabolic dysfunction
Valladolid‐Acebes, I., Berggren, P., & Juntti‐Berggren, L. (2026) · Advances in Biological Regulation · doi:10.1016/j.jbior.2026.101183
Zimerman, A., & Marston, N. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01472-6
Metadata
- Authors
- Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., Mitchell, B. D., Miller, M., O'Connell, J. R., & Shuldiner, A. R.
- Affiliations
- University of Maryland, Baltimore (US)
- Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- Corresponding author
- Pollin, Toni I.
- ORCID
- Venue
- Science
- Published
- 2008-12-12
- Volume
- 322
- Issue
- 5908
- Pages
- 1702-1705
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2673993
- OpenAlex
- W2061100095
- Semantic Scholar
- d46146fa9f89ec4722b99bade97f6a1d685409c0
- Cited by
- 688
- References
- 34
- Citations by year
- 2026: 31 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 30 · 2021: 41 · 2020: 38 · 2019: 36 · 2018: 52 · 2017: 51 · 2016: 54 · 2015: 49 · 2014: 55 · 2013: 43 · 2012: 23
- FWCI
- 22.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01-AG-18728, R01AG018728)
- National Heart, Lung, and Blood Institute (U01HL72515, U01HL084756, U01HL072515, R01HL088119)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK072488)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR046838)
- National Center for Research Resources (M01RR016500, M01RR000052, M01RR 16500)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, plasma lipid profile, triglycerides, HDL cholesterol, LDL cholesterol, coronary artery calcification, subclinical atherosclerosis, cardioprotection, coronary artery disease, lipolysis
- MeSH terms
- Adult, Cholesterol, Christianity, Coronary Artery Disease, Dietary Fats, Fasting, Female, Haplotypes, Heterozygote, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Mutation, Pedigree, Pennsylvania, Risk Factors, Triglycerides, Linkage Disequilibrium, Polymorphism, Single Nucleotide, Apolipoprotein C-III, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.